{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:45:24Z","timestamp":1789854324750,"version":"4.0.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.euroneuro.2011.04.001","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T15:10:10Z","timestamp":1304953810000},"page":"600-620","source":"Crossref","is-referenced-by-count":105,"title":["Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies"],"prefix":"10.1016","volume":"21","author":[{"given":"Alessandro","family":"Zuddas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Usala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.euroneuro.2011.04.001_bb0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-244X-9-72","article-title":"Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data","volume":"17","author":"Acquaviva","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10578-007-0084-3","article-title":"A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder","volume":"39","author":"Akhondzadeh","year":"2008","journal-title":"Child Psychiatry Hum. Dev."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","article-title":"Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism","volume":"34","author":"Akhondzadeh","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/157488610789869265","article-title":"QT alterations in psychopharmacology: proven candidates and suspects","volume":"5","author":"Alvarez","year":"2010","journal-title":"Curr. Drug Saf."},{"issue":"8","key":"10.1016\/j.euroneuro.2011.04.001_bb0025","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0040","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X158075","article-title":"Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003\u20132004","volume":"23","author":"Aparasu","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0055","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0060","first-page":"1130","article-title":"A randomized, double-blind placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents","volume":"29","author":"Arman","year":"2008","journal-title":"Saudi Med. J."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","article-title":"Risperidone augmentation for treatment-resistant aggression in attention deficit\/hyperactivity disorder: a placebo-controlled pilot study","volume":"46","author":"Armenteros","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2009.0022","article-title":"Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability","volume":"20","author":"Arnold","year":"2010","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0075","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/cap.2006.16.665","article-title":"The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s)","volume":"16","author":"Barzman","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopsych.2005.03.019","article-title":"Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children","volume":"58","author":"Biederman","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e31819b95fc","article-title":"Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions","volume":"29","author":"Birkenaes","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1176\/appi.ajp.164.4.537","article-title":"Longitudinal course of pediatric bipolar disorder","volume":"164","author":"Birmaher","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","article-title":"Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study","volume":"44","author":"Blair","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0100","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive\u2013compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","article-title":"Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study","volume":"62","author":"Bruggeman","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00787-008-0715-7","article-title":"Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart review","volume":"18","author":"Brunelle","year":"2009","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":"A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities","volume":"62","author":"Buitelaar","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euroneuro.2005.11.002","article-title":"Diabetes mellitus and antipsychotic treatment in the United Kingdom","volume":"16","author":"Carlson","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0135","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","article-title":"Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach","volume":"18","author":"Castro-Fornieles","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0140","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/cap.2006.0007","article-title":"Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder","volume":"18","author":"Connor","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0170","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0175","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"A doubleblind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania","volume":"41","author":"DelBello","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.chi.0000194567.63289.97","article-title":"A double blind randomized pilot study comparing quetiapine and divalproex for adolescent mania","volume":"45","author":"DelBello","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0185","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-5618.2009.00728.x","article-title":"A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder","volume":"11","author":"DelBello","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01046402","article-title":"Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function","volume":"22","author":"Dollfus","year":"1992","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(02)09678-2","article-title":"Childhood obesity: public-health crisis, common sense cure","volume":"360","author":"Ebbeling","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0205","first-page":"220","article-title":"Focus on ziprasidone: a review of its use in child and adolescent psychiatry","volume":"17","author":"Elbe","year":"2008","journal-title":"J. Can. Acad. Child. Adolesc. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","article-title":"A double-blind pilot study of risperidone in the treatment of conduct disorder","volume":"39","author":"Findling","year":"2000","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0215","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during longterm risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","article-title":"Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study","volume":"28","author":"Findling","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0225","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0230","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0235","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0240","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v69n0401","article-title":"Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges","volume":"69","author":"Fleischhacker","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0245","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","author":"Fraguas","year":"2010","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0255","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","article-title":"Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review","volume":"28","author":"Gao","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archpsyc.65.10.1125","article-title":"Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome","volume":"65","author":"Geller","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0265","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/01.chi.0000171904.23947.54","article-title":"Hematological adverse events in clozapine-treated children and adolescents","volume":"44","author":"Gerbino-Rosen","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0270","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","article-title":"Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial","volume":"43","author":"Gilbert","year":"2004","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0280","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0285","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00004583-200310000-00014","article-title":"Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination","volume":"42","author":"Gonzalez-Heydrich","year":"2003","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0290","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.euroneuro.2008.07.005","article-title":"Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report.","volume":"18","author":"Goodwin","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0295","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00702-002-0803-7","article-title":"Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia","volume":"110","author":"Gothelf","year":"2003","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0300","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/cap.2007.0098","article-title":"Treating disruptive behavior disorders with risperidone: a 1-year, openlabel safety study in children and adolescents","volume":"18","author":"Haas","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1399-5618.2009.00750.x","article-title":"Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Haas","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0310","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0315","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4088\/JCP.v67n0304","article-title":"Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study","volume":"67","author":"Hirschfeld","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0320","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double blind placebo controlled pilot study of Olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-0327(02)00332-4","article-title":"The prevalence and disability of bipolar spectrum disorders in the US population: reanalysis of the ECA database taking into account subthreshold cases","volume":"73","author":"Judd","year":"2003","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0330","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/appi.ps.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0335","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/appi.ajp.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0340","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1089\/cap.2009.0018","article-title":"Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns","volume":"19","author":"Koelch","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0345","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0350","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00004583-199705000-00022","article-title":"Case study: risperidone-induced hepatotoxicity in pediatric patients","volume":"36","author":"Kumra","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0355","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0360","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0365","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-related abnormal involuntary movements, and metabolic and endocrine side effects in children and adolescents","volume":"17","author":"Laita","year":"2007","journal-title":"J. Child. Adolesc. Psychopharmacology."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0370","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(09)61376-3","article-title":"Autism","volume":"374","author":"Levy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0380","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11940-010-0073-x","article-title":"Tourette's disorder","volume":"12","author":"Lyon","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0385","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","article-title":"Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness","volume":"41","author":"Malone","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0390","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0395","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.chi.0000242240.69678.c4","article-title":"Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder","volume":"46","author":"McClellan","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0645","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"McCracken","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0400","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0405","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0410","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0415","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.clinthera.2010.03.003","article-title":"Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder","volume":"32","author":"Miceli","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0420","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1592\/phco.30.2.127","article-title":"Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder","volume":"30","author":"Miceli","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0430","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.64.9.1032","article-title":"National trends in the outpatient diagnosis and treatment of bipolar disorder in youth","volume":"64","author":"Moreno","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0435","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo controlled, double blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0440","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2008.0130","article-title":"Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review","volume":"19","author":"Neuhut","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0445","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0450","first-page":"13","article-title":"Trends in antipsychotic drug use by very young, privately insured children","volume":"49","author":"Olfson","year":"2010","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0455","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0460","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/070674370905401104","article-title":"Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications","volume":"54","author":"Panagiotopoulos","year":"2009","journal-title":"Can. J. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0465","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0470","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1176\/appi.ps.61.3.325","article-title":"Weighing the evidence for pediatric antipsychotic use","volume":"61","author":"Pathak","year":"2010","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0475","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrn2513","article-title":"Why do many psychiatric disorders emerge during adolescence?","volume":"9","author":"Paus","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0480","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/cap.2009.0051","article-title":"Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality","volume":"19","author":"Penzner","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0485","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chc.2008.06.010","article-title":"Developing drugs for core social and communication impairment in autism","volume":"17","author":"Posey","year":"2008","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0490","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0495","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0500","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0505","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0510","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0520","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0525","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine\u2013olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0530","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0535","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0540","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of antipsychotics in early onset schizophrenia and schizoaffective disorder","volume":"165","author":"Sikich","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0545","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110201600410","article-title":"The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability","volume":"16","author":"Silke","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0650","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.schres.2009.07.011","article-title":"Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour","volume":"115","author":"Smith","year":"2009","journal-title":"Schizophr Res."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0550","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0555","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1399-5618.2005.00262.x","article-title":"Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology","volume":"7","author":"Soutullo","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0560","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2006.16.317","article-title":"The effect of long-term antipsychotic treatment on prolactin","volume":"16","author":"Staller","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0565","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1469-7610.2009.02129.x","article-title":"Youth meeting symptom and impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiry","volume":"51","author":"Stringaris","year":"2010","journal-title":"J. Child. Psychol. Psychiatry."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0570","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrneurol.2009.117","article-title":"Managing bipolar disorders in children and adolescents","volume":"5","author":"Taylor","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0575","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0580","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0585","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.08m04726","article-title":"Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit\/hyperactivity disorder: a pilot randomized clinical trial","volume":"70","author":"Tramontina","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0590","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long term effects of Risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0595","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism","volume":"27","author":"Troost","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0600","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1542\/peds.110.3.e34","article-title":"Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs","volume":"110","author":"Turgay","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0605","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/104454601750143348","article-title":"Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial","volume":"11","author":"Van Bellinghen","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0610","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","article-title":"Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies","volume":"121","author":"Verdoux","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0615","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0620","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/1044546041648977","article-title":"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine","volume":"14","author":"Wehmeier","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0625","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"issue":"26","key":"10.1016\/j.euroneuro.2011.04.001_bb0635","first-page":"1","article-title":"A three-country comparison of psychotropic medication prevalence in youth","volume":"2","author":"Zito","year":"2008","journal-title":"Child. Adolesc. Psychiatry. Ment. Health."},{"key":"10.1016\/j.euroneuro.2011.04.001_bb0640","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2000.10.79","article-title":"Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation","volume":"10","author":"Zuddas","year":"2000","journal-title":"J. Child Adolesc. Psychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T17:00:13Z","timestamp":1560186013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":127,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0924977X11000708"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.04.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}